Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance?

被引：15

作者：

Larsen, Erling ^{[1
]}

Blaakaer, Jan ^{[1
]}

机构：

[1] Aarhus Univ Hosp, Dept Gynecol & Obstet, DK-8200 Aarhus N, Denmark

来源：

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA | 2009年 / 88卷 / 04期

关键词：

Ovarian cancer; chemotherapy; time interval; surgery; prognosis; CARCINOMA; SURVIVAL; KINETICS; REMOVAL; GROWTH; TUMOR;

D O I：

10.1080/00016340902814559

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Worldwide, much effort is used every day to perform optimal surgery in the treatment of epithelial ovarian cancer. Treatment of ovarian cancer is a combination of surgery with optimal debulking followed by chemotherapy. However, the optimal timing of postoperative chemotherapy for ovarian cancer remains poorly defined. The literature is made up of seven studies performed in different ways and which have included varying prognostic factors. The general supposition is that the time interval (TI) does not have a prognostic influence but experimental studies have shown that it does affect the prognosis of the cancer. This commentary focuses on the importance of the TI between surgery and postoperative chemotherapy in this horrible disease.

引用

页码：373 / 377

页数：5

共 11 条

[1] Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? [J].

Aletti, Giovanni D. ;

Long, Harry J. ;

Podratz, Karl C. ;

Cliby, William A. .

GYNECOLOGIC ONCOLOGY, 2007, 104 (01) :212-216

[2]

FISHER B, 1983, CANCER RES, V43, P1488

[3] Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer? [J].

Flynn, PM ;

Paul, J ;

Cruickshank, DJ .

GYNECOLOGIC ONCOLOGY, 2002, 86 (03) :354-357

[4] Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: Results of a multicenter retrospective Italian study [J].

Gadducci, A ;

Sartori, E ;

Landoni, F ;

Zola, P ;

Maggino, T ;

Maggioni, A ;

Cosio, S ;

Frassi, E ;

LaPresa, MT ;

Fuse, L ;

Cristofani, R .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :751-758

[5]

GUNDUZ N, 1979, CANCER RES, V39, P3861

[6] A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer [J].

Kiguchi, K ;

Kubota, T ;

Aoki, D ;

Udagawa, Y ;

Yamanouchi, S ;

Saga, M ;

Amemiya, A ;

Sun, FX ;

Nozawa, S ;

Moossa, AR ;

Hoffman, RM .

CLINICAL & EXPERIMENTAL METASTASIS, 1998, 16 (08) :751-756

[7] Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer [J].

Paulsen, Torbjorn ;

Kaern, Janne ;

Kjaerheim, Kristina ;

Haldorsen, Tor ;

Trope, Claes .

GYNECOLOGIC ONCOLOGY, 2006, 102 (03) :447-452

[8] The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma [J].

Rosa, DD ;

Clamp, A ;

Mullamitha, S ;

Ton, NC ;

Lau, S ;

Byrd, L ;

Clayton, R ;

Slade, RJ ;

Kitchener, HC ;

Shanks, JH ;

Wilson, G ;

McVey, R ;

Hasan, J ;

Swindell, R ;

Jayson, GC .

EJSO, 2006, 32 (05) :588-591

[9] Loss of ovarian function promotes angiogenesis in human ovarian carcinoma [J].

Schiffenbauer, YS ;

Abramovitch, R ;

Meir, G ;

Nevo, N ;

Holzinger, M ;

Itin, A ;

Keshet, E ;

Neeman, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (24) :13203-13208

[10] Prognostic importance of the time interval from surgery to chemotherapy in treatment of ovarian carcinoma [J].

Sorbe, B .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2004, 14 (05) :788-793

← 1 2 →